Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Acute Agitation And Aggression Treatment Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The acute agitation and aggression treatment market has experienced robust expansion in recent years. It is projected to climb from $6.05 billion in 2025 to $6.36 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.2%. Historically, this growth can be ascribed to elements such as the rising incidence of psychiatric disorders, an uptick in emergency department visits for agitation, broader access to antipsychotic medications, the development of mental health services, and increased understanding of behavioral health conditions.
The acute agitation and aggression treatment market size is anticipated to experience robust expansion in the coming years. It is projected to reach $8.37 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period can be ascribed to an escalating need for swift-acting therapeutic solutions, increased financial backing for neuropsychiatric drug research, the burgeoning utilization of digital mental health resources, the broadening of integrated behavioral care frameworks, and a heightened emphasis on patient-centered treatment methodologies. Significant trends for the forecast duration encompass the wider embrace of rapid-onset pharmacological therapies, a growing emphasis on individualized psychiatry methods, the expanding incorporation of digital oversight instruments, the extension of emergency behavioral care procedures, and a stronger commitment to patient well-being.
Get A Free Sample Report With In-Depth Market Insights:
Acute Agitation And Aggression Treatment Market Growth Factors Behind Sustained Expansion
The rising occurrence of dementia is projected to fuel the expansion of the acute agitation and aggression treatment market moving forward. Dementia encompasses conditions characterized by compromised memory, cognitive function, and the ability to perform daily activities. Agitation, a symptom frequently observed in dementia patients, manifests through behaviors such as restlessness, repetitive actions, or frequent hand movements. Treating acute agitation and aggression holds significant importance in dementia care, as it lessens the danger of harmful symptoms, enhances the patient’s quality of life, and addresses the underlying reasons for the agitation. For example, in February 2023, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 401,300 Australians had dementia in 2022, a figure anticipated to nearly double to 849,300 by 2058. Thus, the growing incidence of dementia is a key driver for the acute agitation and aggression treatment market’s growth.
Acute Agitation And Aggression Treatment Market Segmentation: How Does The Market Break Down By Category?
The acute agitation and aggression treatment market covered in this report is segmented –
1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users
Subsegments:
1) By Behavioral Approaches: Cognitive Behavioral Therapy (CBT), De-escalation Techniques, Psychoeducation, Relaxation Therapy, Other Behavioral Interventions
2) By Environmental Interventions: Sensory Modifications, Safe Room Or Containment Strategies, Environmental Noise Reduction, Lighting And Temperature Adjustments, Other Environmental Interventions
3) By Pharmacologic Approaches: Antipsychotic Medications, Benzodiazepine Medications, Mood Stabilizers, Other Pharmacologic Agents, Adjunctive Medications
Acute Agitation And Aggression Treatment Market Industry Trends Fueling Future Revenue Growth
Leading companies active in the acute agitation and aggression treatment market are concentrating on the development of innovative products, such as a generic variant of Zyprexa, to cater to patient needs. Generic Zyprexa is a rendition of the brand-name drug Zyprexa, which comprises olanzapine as its active ingredient and is utilized for managing psychotic conditions. For example, in September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, released a generic version of Zyprexa. This atypical antipsychotic medicine is indicated for addressing acute agitation connected with schizophrenia and bipolar I mania.
Acute Agitation And Aggression Treatment Market Competitive Overview And Top Companies
Major companies operating in the acute agitation and aggression treatment market are Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc
View The Full Acute Agitation And Aggression Treatment Market Report:
Acute Agitation And Aggression Treatment Market Regional Analysis And Top Geography
North America was the largest region in the acute agitation and aggression treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute agitation and aggression treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.